+143.3%
MRNA vs GSK
-8.9%
+152.2%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 6mo.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.4% | +0.2% | -3.5% | -3.8% |
| 7D | -10.1% | -3.6% | -6.5% | -1.4% |
| 30D | +126.7% | -5.9% | +132.7% | +178.4% |
| 3M | +184.1% | -4.3% | +188.4% | +243.9% |
| 6M | +143.3% | -10.8% | +154.1% | +195.1% |
| All | +143.3% | -8.9% | +152.2% | +195.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 6mo: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
6mo analysis · Full analysis span regression · 6 months rolling